Results 51 to 60 of about 2,896 (157)
Economic Burden of Chronic Lymphocytic Leukaemia in Australia
European Journal of Haematology, Volume 117, Issue 6, Page 1541-1551, December 2026.ABSTRACT Background
The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods
A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...Lan Gao, Dieu Nguyen, Victoria White, Patricia M. Livingston, Chan Y. Cheah +4 morewiley +1 more sourceHigh Level of Component C1q Binding Protein (C1QBP) is Associated With Poor Prognosis and Dysfunction of Mast Cells in Lung Adenocarcinoma
Cancer Medicine, Volume 15, Issue 11, November 2026.ABSTRACT Background
Component C1q binding protein (C1QBP) is known as an important regulator of mitochondrial plasticity and is involved in antitumor immune response in cancers. Nevertheless, its role in lung adenocarcinoma (LUAD) still remains largely unknown.Wei Li, Guangnan Huang, Lizhong Zeng, Wenhui Dang, Ting Jiao, Yonghong Zhang, Mengying Zhang, Shuru Zhou, Liping Chen, Shuanying Yang +9 morewiley +1 more sourceAge, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study
Cancer Medicine, Volume 15, Issue 11, November 2026.ABSTRACT Introduction
Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.Kevin Nasrinfar, Harrison Wildhaber, Rudolf Rohr, Gaëlle Rhyner Agocs, Urban Novak, Alessandra Curioni‐Fontecedro, Vérène Dougoud‐Chauvin +6 morewiley +1 more sourceIndirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Oncology and TherapyIntroduction Compared with chemoimmunotherapy, both zanubrutinib monotherapy and venetoclax plus obinutuzumab prolong progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL). Matching-adjusted indirect comparison (MAIC) can be Talha Munir, Nicolás Martinez-Calle, Sheng Xu, Keri Yang, Xiaoyun Ge, Ayad K. Ali, Leyla Mohseninejad, Balázs Dobi, Pal Rakonczai, Han Ma, Rhys Williams, Wassim Aldairy, Nicole Lamanna +12 moredoaj +1 more sourceIbrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans
Blood Advances, 2019 : The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has proven to be efficacious in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and related diseases.Gasim Dobie, Fahd A. Kuriri, Musab M.A. Omar, Fehaid Alanazi, Ali M. Gazwani, Chloe P.S. Tang, Daniel Man-yuen Sze, Sasanka M. Handunnetti, Constantine Tam, Denise E. Jackson +9 moredoaj +1 more sourceImpact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC
HemaSphere, Volume 10, Issue 11, November 2026.Abstract
The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...Candida Vitale, Thomas Chatzikonstantinou, Christina Papangelou, Francesca Perutelli, Maria Chiara Montalbano, Giulia Bondielli, Elia Boccellato, Salem Alshemmari, Francesco Angotzi, Miguel Arguello‐Tomas, Tomas Arpas, Sandra Bašić‐Kinda, Sotiria Besikli‐Dimou, Łukasz Bołkun, Tomasz Buczek, Aleksandra Butrym, Katherine Chapis, Sofia Chatzileontiadou, Rosa Collado, Raul Cordoba Mascuñano, Lorenzo De Paoli, Marina Deodato, Maria Dimou, David Donaldson, Joanna Drozd‐Sokołowska, Salem Elias, Andrea Ferrario, Alberto Fresa, Anna Maria Frustaci, Rocío García‐Serra, Ajay Gogia, Isabel González‐Gascón‐y‐Marín, Vasko Graklanov, Maria Hryniewiecka, Zhu Huayuan, Elzbieta Iskierka‐Jażdżewska, Paula Jablonowska‐Babij, Ozren Jaksic, Elzbieta Kalicińska, Maria Kislova, Maya Koren‐Michowitz, Epameinondas Koumpis, Zuzana Kubová, Jorge Labrador, Pietro Lauzzana, Shai Levi, Francesca Martini, Mariia Mikhaleva, Eva Minga, Riccardo Moia, Elżbieta Morawiec‐Szymonik, Marta Morawska, Femke V. M. Mulder, Roberta Murru, Jacopo Olivieri, Ewa Paszkiewicz‐Kozik, Lata Rani, Josep Maria Roncero, Wojciech Salamon, Alessandro Sanna, Lydia Scarfò, Tereza Shokralla, Martin Šimkovič, Matevž Škerget, Emil Spasov, Antigoni Tranidou, Jagoda Tryc‐Szponder, Marzia Varettoni, Andrea Visentin, George Vrachiolias, David Waddell, Ewa Wasik‐Szczepanek, Kamil Wdowiak, Mateusz Wilk, Kamil Wiśniewski, Magdalena Witkowska, Mohamed Yassin, Seyma Yıldız, Klaudia Zielonka, Nil Albiol, Jennifer R. Brown, Benedetto Bruno, Mark Catherwood, Anastasia Chatzidimitriou, Michael Doubek, Gianluca Gaidano, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Krzysztof Jamroziak, Ioannis Kotsianidis, Luca Laurenti, Eugene Nikitin, Maria Papaioannou, Tomáš Papajik, Martin Špaček, Niki Stavroyianni, Josephine M. I. Vos, Tomasz Wróbel, Münci Yağcı, Arnon P. Kater, Matthew Davids, Petra Langerbeins, Kostas Stamatopoulos, Paolo Ghia, Marta Coscia +106 morewiley +1 more sourceZanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results
Blood Advances: Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib (ibr) revolutionized chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treatment, although treatment-related toxicities limit the use of some BTK inhibitors.Mazyar Shadman, John M. Burke, Jennifer Cultrera, Habte A. Yimer, Syed F. Zafar, Jamal Misleh, Subramanya S. Rao, Charles M. Farber, Aileen Cohen, Hui Yao, Adam Idoine, Qi An, Ian W. Flinn, Jeff P. Sharman +13 moredoaj +1 more sourceFixed‐duration glofitamab in patients with relapsed or refractory follicular lymphoma: Results from a Phase 1/2 study
HemaSphere, Volume 10, Issue 11, November 2026.Abstract
More effective options are needed to personalize treatment for relapsed/refractory (R/R) follicular lymphoma (FL) by balancing efficacy, safety, and accessibility. We report efficacy and safety of glofitamab, a CD20xCD3 T‐cell engaging bispecific antibody, from a Phase 1/2 study in patients with R/R FL after ≥2 prior therapies.Franck Morschhauser, Lorenzo Falchi, Carmelo Carlo‐Stella, Emmanuel Bachy, Michael Crump, Fritz Offner, Martin Hutchings, Anna Sureda, Krish Patel, Mark Hertzberg, Sirpa Leppa, Sonia Gonzalez de Villambrosia, Estefania Mulvihill, James Relf, Alessia Bottos, Vanessa Breton, Pauline Baumlin, Kathryn Humphrey, Linda Lundberg, Michael Dickinson +19 morewiley +1 more sourceA randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings
Frontiers in ImmunologyBackgroundCytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)–related respiratory failure.Steven P. Treon, Camille N. Kotton, David J. Park, Giorgia Moranzoni, Camilla K. Lemvigh, Joseph C. Gathe, Tilly A. Varughese, Christopher F. Barnett, Johnny M. Belenchia, Nina M. Clark, Charles M. Farber, Muhammad Bilal Abid, Gulrayz Ahmed, Christopher J. Patterson, Maria L. Guerrera, Jacob D. Soumerai, Vipheaviny A. Chea, Isabel P. Carulli, Jackson Southard, Shuqiang Li, Catherine J. Wu, Kenneth J. Livak, Eric Holmgren, Pil Kim, Carrie Shi, Holly Lin, Vanitha Ramakrishnan, Ying Ou, Scott Olszewski, Lars Rønn Olsen, Derin B. Keskin, Derin B. Keskin, Zachary R. Hunter, Christopher Tankersley, Todd Zimmerman, Binod Dhakal +35 moredoaj +1 more source